ZEMANOVA, Milada, Robert PIRKER, Lubos PETRUZELKA, Zuzana ZBOŽÍNKOVÁ, Dragana JOVANOVIC, Mirjana RAJER, Krisztina BOGOS, Gunta PURKALNE, Vesna CERIMAN, Subhash CHAUDHARY, Igor RICHTER, Jiri KUFA, Lenka JAKUBÍKOVÁ, Marius ZEMAITIS, Marketa CERNOVSKA, Leona KOUBKOVA, Zdenka VILASOVA, Karin DIECKMANN, Attila FARKAS, Jelena SPASIC, Kateřina FRÖHLICH, Andreas TIEFENBACHER, Virag HOLLOSI, Juraj KULTAN, Iveta KOLAROVA and Jiri VOTRUBA. Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience. RADIOLOGY AND ONCOLOGY. Ljubljana: Association of Radiology and Oncology, 2020, vol. 54, No 2, p. 209-220. ISSN 1318-2099. Available from: https://dx.doi.org/10.2478/raon-2020-0026.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience
Authors ZEMANOVA, Milada (203 Czech Republic, guarantor), Robert PIRKER (40 Austria), Lubos PETRUZELKA (203 Czech Republic), Zuzana ZBOŽÍNKOVÁ (203 Czech Republic, belonging to the institution), Dragana JOVANOVIC (688 Serbia), Mirjana RAJER (705 Slovenia), Krisztina BOGOS (348 Hungary), Gunta PURKALNE (428 Latvia), Vesna CERIMAN (688 Serbia), Subhash CHAUDHARY (203 Czech Republic), Igor RICHTER (203 Czech Republic), Jiri KUFA (203 Czech Republic), Lenka JAKUBÍKOVÁ (203 Czech Republic, belonging to the institution), Marius ZEMAITIS (440 Lithuania), Marketa CERNOVSKA (203 Czech Republic), Leona KOUBKOVA (203 Czech Republic), Zdenka VILASOVA (203 Czech Republic), Karin DIECKMANN (40 Austria), Attila FARKAS (348 Hungary), Jelena SPASIC (688 Serbia), Kateřina FRÖHLICH (203 Czech Republic, belonging to the institution), Andreas TIEFENBACHER (40 Austria), Virag HOLLOSI (348 Hungary), Juraj KULTAN (203 Czech Republic), Iveta KOLAROVA (203 Czech Republic) and Jiri VOTRUBA (203 Czech Republic).
Edition RADIOLOGY AND ONCOLOGY, Ljubljana, Association of Radiology and Oncology, 2020, 1318-2099.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Slovenia
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.991
RIV identification code RIV/00216224:14110/20:00115905
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.2478/raon-2020-0026
UT WoS 000537450400008
Keywords in English diagnostic procedures; multimodality treatment; non-small-cell lung cancer; stage III
Tags 14110215, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/7/2020 12:36.
Abstract
Background. Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the realworld setting in Central European countries to define areas for improvements. Patients and methods. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Results. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. Conclusions. The real-world study demonstrated a broad heterogeneity in the management of stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.
PrintDisplayed: 21/7/2024 06:31